Both when EGFR-expression was evaluated using HGU133 microarrays and when using RNA-sequencing, 17 of the 19 models demonstrated a robust correlation between EGFR-expression level and relative Erlotinib-induced tumor regression (Supplemental Fig. S2). The gene discussed is EGFR; the disease is neoplasm.